British drug giant AstraZeneca is rushing forward a big clinical trial for its blood cancer drug Calquence because it has shown early promising results in later-stage COVID-19 patients—those in intensive care units and on ventilators. Calquence and top-selling leukemia drug Imbruvica are the latest hopes in getting coronavirus patients off ventilators, where there is a 50% mortality rate.  

英国制药巨头阿斯利康公司(AstraZeneca)正在为其血癌药物Calquence进行大规模临床试验，因为它已经在晚期covid19患者(重症监护病房和呼吸机患者)身上展示了早期的有希望的结果。Calquence和最畅销的白血病药物Imbruvica是让冠状病毒患者远离呼吸器的最新希望，因为那里有50%的死亡率